Proinflammatory and antiinflammatory cytokines in malignant haematologic diseases;Zápalové a protizápalové cytokíny pri zhubných hematologických ochoreniach

Klinicka Onkologie

Volumn 16, Issue 1, 2003, Pages 19-23

  Sakalova A ^a   Skultetyova D ^c   Bucova M ^d   Holomanova D ^a   Skultety J ^b   Lipsic T ^a   Pokorna G ^a   Mistrik M ^a   Steruska M ^a   Bojtarova E ^a   Desser, L ^e   Dedik L ^f  

^a SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^b FN Bratislava   (Slovakia)

^c Slovensky ustav srdcovych a clevnych   (Slovakia)

^d Ustav Imunologie LFUK Bratislava   (Slovakia)

^e Narodny Onkologicky Ustav   (Slovakia)

^f SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

Author keywords

Hematologic malignancies; IL 6; TNF receptors; Transforming growth factor (TgF 1); Tumor necrosis factor (TNF)

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CYTOKINE RELEASE; DISEASE ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; IMMUNE SYSTEM; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONITORING; MULTIPLE MYELOMA; PROGNOSIS; REMISSION; RISK ASSESSMENT;

EID: 0038036633     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Abbas, A.K., Lichtman, A.H., Pober, J.S.: Cellular and molecular immunology. 3rd edition, Ed.: W.B. Sanders Company, 1997, s.494.
2. th edition, Ed.: W.M. Freeman and Company, 2000, s.670.
3. Bačovský, J., Ščudla, V.: Cytokinová sít́ u mnohotného myelomu. Vnitřnílék. 1994, 40, č.8, s. 517-520.
4. Blobe, G.C., Schiemann, W.P., Lodish, H.F.: Role of transforming growth factor in human disease. N.Engl.J.Med. 342, 2000, s.274-279.
5. Bucová, M.: Chemokiny, rast nádorov a angiogenéza. Bratisl. Lek Listy, 102, 2001, s. 22-27.
6. Bucová, M.: Úloha cytokínov v rozvoji lokálneho a systémového zápalu a septického šoku. Vnitřní lék 48, 2002, č.7 (v tlači).
7. Delves, P.J., Roitt, I.M.: Encyclopedia of immunology. Second edition. Academic Press. Harcourt Brace @ Company Publishers. San Diego, London, Boston, New York, Syndey, Tokyo, Toronto., 1998, s.1869-2516.
8. Desser, L., Holomáňová, D., Závadová, E., Sakalová, A., Mohr, T.: Oral therapy with proteolytic enzymes decreases TGF-β levels in human blood. Cancer Chemother. Pharmacol. 47, 2001, s. 10-16.
9. Desser, L., Sakalová, A., Závadová, E., Holomáňová, D., Mohr, T.: Concentrations of soluble tumor necrosis factor receptors, β2-microglobulin, IL-6 and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme - chemotherapy. Int. J. Immunotherapy XIII, 1997, 3/4, s. 121-130.
10. Gebauer, F., Michael, B., Stauder, G., Ransberger, K., Kunze, R.: Proteolytic enzymes modulate the adhesion molecule CD44 on malignant cells in vitro. Int. J.Immunother 13, 1997, s. 111-121.
11. Kushner, I.: C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging. Cleveland Clinic Journal, 68, 2001, s. 535-537.
12. Montes-Borinaga, A.: Interleukin-6 is a cofacor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro. Brit.J.Haematol, 76, 1990, s. 476-483.
13. Tilg, H., Dinarello, A.CH., Mier, J.V.: IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today, 18, 1997, s. 428-432.
14. Sakalová, A., Vaňásek, J., Bláha, M., Tichý, M., Zadák, Z.: Multiple myeloma and paraproteinemias. SAP Bratislava, 1995, s. 173.
15. Sakalová, A., Bock, P.R., Dedík, L., Hanisch, J., Schiess, W., Gažová, S., Chabroňová, I., Holomáňová, D., Mistrík, M., Hrubiško, M.: Retrolective cohort study of an additive therapy with oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol, 2001, 47, Suppl., s. 38-44.
16. Sakalová, A., Desser, L., Bucová, M., Stauder, G., Ransberger, K.: Recent immunological approaches and therapy of multiple myeloma. J of Health Management and Public Health, 3, 1998, s. 47-53.
17. Zhang, X.G., Klein, B, Bataille, R.: Interleukin 6 is a potent myeloma cell growth factor in patients with aggressive multiple myeloma. Blood, 74, 1989, s. 11-13.
18. Ščudla, V., Kubalová, D., Bačovský, J., Lukeš, J., Vavrdová, V.: Přípěvek k vyšetření solubilního receptoru interleukinu-6 v séru u mnohopočetného myelomu. Čas. Lek. Čes., 135, 1996, s. 719-722.
19. Ščudla, V., Budíková, M., Bačovský, J., Ordeltová, M., Opíchalová, D.: Vztah hladin solubilních cytoadhezivních molekul VCAM-1 a ICAM-1 k vybraným ukazatelum mnohočetného myelomu. Vnitř. Lék. 45, 1999, s. 583-590.
20. Sakalová, A., Chabroňová, I., Gažová, S., Škultétyová, D., Škultéty, J., Mistrík, M., Hrubiško, M.: Kostné zmeny pri mnohopočetnom myelóme - súčasné etiopatogenetické, diagnostické a liečebné aspekty. Vnitř. Lék. 48, 2002, s.642-648.